Northern Trust’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
– Sell
-8,731
Closed -$43K – 4331
2019
Q4
$43K Sell
8,731
-94
-1% -$608 ﹤0.01% 4082
2019
Q3
$70K Hold
8,825
– – ﹤0.01% 3997
2019
Q2
$64K Hold
8,825
– – ﹤0.01% 4042
2019
Q1
$70K Buy
8,825
+1,900
+27% +$17.9K ﹤0.01% 3989
2018
Q4
$55K Sell
6,925
-20
-0.3% -$240 ﹤0.01% 4035
2018
Q3
$107K Buy
6,945
+4,319
+164% +$52K ﹤0.01% 4013
2018
Q2
$23K Hold
2,626
– – ﹤0.01% 4206
2018
Q1
$23K Hold
2,626
– – ﹤0.01% 4157
2017
Q4
$27K Buy
2,626
+22
+0.8% +$266 ﹤0.01% 4133
2017
Q3
$40K Buy
+2,604
New +$30.7K ﹤0.01% 4091
2016
Q4
– Sell
-288
Closed -$4K – 4221
2016
Q3
$4K Hold
288
– – ﹤0.01% 4163
2016
Q2
$10K Hold
288
– – ﹤0.01% 4164
2016
Q1
$8K Hold
288
– – ﹤0.01% 4183
2015
Q4
$13K Hold
288
– – ﹤0.01% 4196
2015
Q3
$52K Buy
288
+27
+10% +$5.32K ﹤0.01% 4065
2015
Q2
$37K Sell
261
-23
-8% -$3.19K ﹤0.01% 4100
2015
Q1
$39K Sell
284
-26
-8% -$4.25K ﹤0.01% 4181
2014
Q4
$55K Sell
310
-161
-34% -$28.6K ﹤0.01% 4080
2014
Q3
$113K Sell
471
-162
-26% -$54.1K ﹤0.01% 4002
2014
Q2
$277K Buy
633
+9
+1% +$4.15K ﹤0.01% 3760
2014
Q1
$285K Buy
624
+19
+3% +$9.87K ﹤0.01% 3694
2013
Q4
$291K Sell
605
-2
-0.3% -$978 ﹤0.01% 3625
2013
Q3
$292K Sell
607
-739
-55% -$354K ﹤0.01% 3558
2013
Q2
$633K Buy
+1,346
New +$610K ﹤0.01% 3407

Other funds holding IDXG

Northern Trust's IDXG Position: Q1 2020 in Review

Northern Trust sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q1 2020, closing a stake of 8,731 shares — an estimated $43K sold.

Northern Trust first reported a position in IDXG in Q2 2013 and held it in 24 quarters. The position peaked at $633K in Q2 2013. 15 funds tracked by Wall St. Rank hold IDXG as of Q1 2020.

  • Northern Trust reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Northern Trust sold 8,731 Interpace Biosciences, Inc. Common Stock shares in Q1 2020, an estimated $43K.
  • Northern Trust first reported a position in Interpace Biosciences, Inc. Common Stock in Q2 2013 and held it in 24 quarters.
  • Northern Trust's Interpace Biosciences, Inc. Common Stock position peaked at $633K in Q2 2013.
  • 15 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q1 2020.

Based on Northern Trust's 13F filing for Q1 2020, filed 14 May 2020.